Federal prime contract award
Recipient: MAPP BIOPHARMACEUTICAL, INC.
Awarding agency: Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response
Description: THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.
Award type: DEFINITIVE CONTRACT
Award amount: $110877385.03
Total outlays: $58760491.54
Period of performance: 2022-09-28 to 2031-05-01
NAICS: 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC: AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
Place of performance (state): CA